Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Inhibrx Biosciences Q3 2026 Results: Net Loss of $38.7M, Loss Widens

Inhibrx Biosciences reported a net loss of $108.8 million for the nine months ended September 30, 2026, compared to $107.2 million in the prior year. The company significantly increased its cash position to $199.5 million following $175.0 million in debt proceeds, while its accumulated deficit grew to $355.0 million.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue2.00.0
Profit before tax-38.7-35.3
Net income-38.7-35.3
EPS (diluted, $ a share)$-2.46$-2.28

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: INBX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Inhibrx Biosciences, Inc.: key numbers

Share price
$74.18Close, Nov 17
Market cap
$1.1B
Shares outstanding
14.77MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Inhibrx Biosciences, Inc.

All →
4:08 PM ET 8-K
Financial Results

Inhibrx Biosciences Financial Results

Inhibrx Biosciences reported Q3 2026 financial results, highlighting a cash position of $199.5 million and $2.0 million in revenue from a licensing agreement with Pfizer. The company is advancing its clinical pipeline, with upcoming data presentations for ozekibart in Ewing sarcoma and ongoing enrollment in the Phase 2 HexAgon study for ordastobart.

Term
Q3 2026
6:58 PM ET Form 4
Insider Buying

Inhibrx Biosciences CEO Mark Lappe Buys $832K of Stock

Mark Lappe, CEO, bought 9,840 shares of Inhibrx Biosciences, Inc. at $84.07 to $85.00 a share (average $84.54) in 4 transactions, worth $832K in total on Oct 14, 2026. Shares held after the trade: 169,900 (+1.5%).

Value
$832K
Shares
9,840
Average price
$84.54
Role
CEO
Holding change
+1.5%
Trade date
Oct 14, 2026
5:04 PM ET 8-K
Investor Presentation

Inhibrx Biosciences Investor Presentation

Inhibrx Biosciences, Inc. has updated its corporate investor presentation, which is being used for meetings and conferences with the investment community. The presentation provides a summary of the company's business strategy and clinical pipeline updates for its investigational product candidates.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.